Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOPHO-AML 2004: Gemtuzumab ozogamicin in pediatric AML
NCT00476541Phase 3Completed
- Sponsor
- Aarhus University
- Start
- Jan 2004
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Aarhus University. Started Jan 2004; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00476541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00476541.